Yazar "Sargın, Fatma Deniz" için Bildiri Koleksiyonu listeleme
-
Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO)
Sevindik, Ömür Gökmen; Gemici, Aliihsan; Usta, Furkan Selim; Çakır, Aslı; Sadri, Sevil; Bekoz, Hüseyin; Sargın, Fatma Deniz (The American Society of Hematology, 2019)Gemtuzumab Ozogamycin (GO) is a drug conjugated monoclonal antibody which targets CD33 an antigen highly expressed on the surface of AML blasts. GO is approved for the treatment of both newly-diagnosed and relapsed AML. ... -
HLA-A allele mismatch (7/8 or 9/10) is the second best option after 8/8 or 10/10 matched unrelated donors: An analysis on results from Turkish centers
Beksaç, Meral; Savran Oğuz, Fatma; Topçuoğlu, Pervin; Karasu, Gülsun; Arat, Mutlu; Aksoylar, Serap; Kansoy, Savaş; Kalayoğlu Beşışık, Sevgi; Küpesiz, Alphan; Hazar, Volkan; Altuntaş, Fevzi; Ünal, Ali; Gülbaş, Zafer; Sargın, Fatma Deniz; İlhan, Osman; Gürman, Günhan; Yeşilipek, Akif (Nature Publishing Group, 2015)Introduction: Hematopoietic stem cell transplantation (HSCT) from an unrelated donor has been established as an effective treatment option for patients with hematological diseases who lack a human leukocyte antigen ...